Brought to you by 
Pfizer to acquire Idun Pharmaceuticals in cash transaction
09 Mar 2005
Executive Summary
Pfizer has agreed to buy Idun Pharmaceuticals (therapeutics to control apoptosis) for, according to one of Idun's investors, approximately $280mm in cash.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer to acquire Idun Pharmaceuticals in cash transaction
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice